

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Hematology				
Stem cell transplant	G-CSF (CSF3); epidermal growth factor receptor (EGFR)	<p>Mouse studies suggest that antagonizing EGFR could help improve transplant outcomes. In mice, the EGFR inhibitor Tarceva erlotinib plus G-CSF increased hematopoietic and progenitor cell mobilization compared with G-CSF alone. Also in mice, transplantation of bone marrow lacking EGFR resulted in greater mobilization than transplantation of wild-type marrow. Next steps include testing Tarceva in additional mouse models of hematopoietic stem cell transplantation. Astellas Pharma Inc. and Roche market Tarceva erlotinib to treat non-small cell lung cancer (NSCLC) and pancreatic cancer.</p> <p>SciBX 3(38); doi:10.1038/scibx.2010.1151 Published online Sept. 30, 2010</p>	Patent application filed; available for licensing	<p>Ryan, M.A. <i>et al. Nat. Med.</i>; published online Sept. 21, 2010; doi:10.1038/nm.2217</p> <p>Contact: Hartmut Geiger, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio e-mail: hartmut.geiger@cchmc.org</p>